ACE-LY-004 Phase 2 trial

December 17, 2018

Calquence Shows Durable Responses in Relapsed or Refractory Mantle Cell Lymphoma, Phase 2 Trial Shows

News

Calquence (acalabrutinib), a treatment for mantle cell lymphoma (MCL) patients who have failed at least one prior therapy, reduced tumor burden in four of five patients in a Phase 2 clinical ... Read more

January 25, 2018

9 in 10 Mantle Cell Lymphoma Patients Benefit from Calquence, AstraZeneca Reports

News

Calquence (acalabrutinib) eliminated tumors in 40 percent of mantle cell lymphoma patients who took part in a Phase 2 clinical trial, AstraZeneca and Acerta Pharma reported. An additional 41 percent in the ACE-LY-004 trial ... Read more

November 1, 2017November 1, 2017

FDA Grants Accelerated Approval to Calquence for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration has approved AstraZeneca‘s Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The FDA’s accelerated ... Read more